Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Express Scripts
Colorcon
Teva
Cerilliant
Harvard Business School
Daiichi Sankyo
Novartis
Merck
Federal Trade Commission

Generated: January 23, 2018

DrugPatentWatch Database Preview

Peginesatide acetate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for peginesatide acetate and what is the scope of peginesatide acetate freedom to operate?

Peginesatide acetate
is the generic ingredient in two branded drugs marketed by Takeda Pharms Usa and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Peginesatide acetate has one hundred and twelve patent family members in thirty-two countries.

Summary for peginesatide acetate
International Patents:112
US Patents:6
Tradenames:2
Applicants:1
NDAs:1
Clinical Trials: 973
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:peginesatide acetate at DailyMed

US Patents and Regulatory Information for peginesatide acetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-003 Mar 27, 2012 DISCN No No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-005 Mar 27, 2012 DISCN No No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-006 Mar 27, 2012 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-005 Mar 27, 2012 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-002 Mar 27, 2012 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa OMONTYS peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-007 Mar 27, 2012 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-003 Mar 27, 2012 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Takeda Pharms Usa OMONTYS PRESERVATIVE FREE peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-003 Mar 27, 2012 DISCN No No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Takeda Pharms Usa OMONTYS peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-007 Mar 27, 2012 DISCN No No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Takeda Pharms Usa OMONTYS peginesatide acetate SOLUTION;INTRAVENOUS, SUBCUTANEOUS 202799-007 Mar 27, 2012 DISCN No No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for peginesatide acetate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,304,391 Peptides that bind to the erythropoietin receptor ➤ Subscribe
7,855,175 Peptides that bind to the erythropoietin receptor ➤ Subscribe
8,592,365 Spacer moiety for poly(ethylene glycol) modified peptide based compounds ➤ Subscribe
7,906,485 Erythropoietin receptor peptide formulations and uses ➤ Subscribe
8,324,159 Erythropoietin receptor peptide formulations and uses ➤ Subscribe
8,729,030 Peptides that bind to the erythropoietin receptor ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for peginesatide acetate

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Mallinckrodt
Deloitte
Cerilliant
Fish and Richardson
Colorcon
Johnson and Johnson
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot